Provided by Tiger Trade Technology Pte. Ltd.

CSTONE PHARMA-B

5.900
+0.3406.12%
Volume:7.94M
Turnover:45.87M
Market Cap:9.42B
PE:-18.74
High:5.950
Open:5.560
Low:5.545
Close:5.560
52wk High:10.410
52wk Low:4.010
Shares:1.60B
HK Float Shares:1.60B
Volume Ratio:1.23
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.315
ROE:-52.14%
ROA:-14.44%
PB:6.24
PE(LYR):-18.74
PS:18.97

Loading ...

New Zealand's Rua Bioscience FY Customer Revenue Jumps on Australia, NZ Growth

Reuters
·
Aug 28

CStone Pharmaceuticals Posts HY Loss of Rmb252.3 Million

Reuters
·
Aug 27

Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Dow Jones
·
Aug 27

China's HBM Holdings H1 Revenue Rises on Progress on Mid-Late Clinical Stage Programs

Reuters
·
Aug 27

Cstone Pharma-B Reports Interim Results with Revenue Surging 314.75% to RMB 205 Million

Stock News
·
Aug 27

China's CStone Pharmaceuticals H1 Revenue Soars on Drug Sales

Reuters
·
Aug 27

CStone Pharmaceuticals - no Dividends Paid, Declared or Proposed During Interim Period

THOMSON REUTERS
·
Aug 27

CStone 1H FY26 Loss Narrows to RMB 252.28 Million; Revenue Rises to RMB 205.1 Million

Reuters
·
Aug 27

CStone Pharmaceuticals H1 Revenue RMB 205.1 Million

THOMSON REUTERS
·
Aug 27

When Will CStone Pharmaceuticals (HKG:2616) Breakeven?

Simply Wall St.
·
Aug 27

CStone Pharmaceuticals' Application for Tumor Drug Gets China Nod in 23 Days

MT Newswires Live
·
Aug 21

CSTONE PHARMA-B Gets NMPA Green Light for CS5007 Investigational New Drug Application

Stock News
·
Aug 21

CStone Says China NMPA Clears IND for Cs5007 Egfr/her3 Bispecific ADC

Reuters
·
Aug 21

CStone Pharmaceuticals - Receives Nmpa Ind Approval for Cs5007 in China

THOMSON REUTERS
·
Aug 21

CStone Pharma Cuts Outstanding Shares by 4.47 Million in July; Confirms Public-Float Compliance

Bulletin Express
·
Aug 06

CStone Pharma Sets 27 August 2026 Board Meeting to Approve H1 2026 Results and Assess Interim Dividend

Bulletin Express
·
Aug 06

Cstone Pharmaceuticals Says Directors and Senior Management Purchase 2.4 Million Shares in June 2026

Reuters
·
Jul 23

CStone directors and executives acquire 2.42 million shares; company cancels 4.60 million buy-backs as CS2009 advances toward global Phase III

Bulletin Express
·
Jul 23

Key Insider Purchases at CStone Pharma-B, Reflecting Confidence in Future Prospects

Stock News
·
Jul 23

Cstone Pharmaceuticals - Directors and Senior Management Purchase 2.4 Mln Shares in June 2026

THOMSON REUTERS
·
Jul 23